Lyme Disease (Borrelia Burgdorferi IgM) - ELISA

Lyme Disease (Borrelia burgdorferi IgM) ELISA Test

The Lyme Disease (Borrelia burgdorferi IgM) ELISA Test is a laboratory blood test used to detect Immunoglobulin M (IgM) antibodies against Borrelia burgdorferi, the bacterium that causes Lyme disease. It is primarily used as a screening test in patients with early symptoms of Lyme disease, particularly within the first few weeks after infection.

Lyme disease is a tick-borne bacterial infection transmitted through the bite of infected Ixodes (black-legged or deer) ticks. It occurs mainly in North America, Europe, and parts of Asia. Early diagnosis and treatment are important to prevent complications affecting the joints, nervous system, heart, and skin.

Early symptoms may include:

• Expanding bull's-eye rash (erythema migrans)
• Fever
• Chills
• Fatigue
• Headache
• Muscle aches
• Joint pain
• Swollen lymph nodes

If untreated, the infection may spread and cause:

• Lyme arthritis
• Facial nerve palsy (Bell's palsy)
• Meningitis
• Peripheral neuropathy
• Lyme carditis

The immune system usually begins producing IgM antibodies within 1–2 weeks after infection, making the IgM ELISA useful for evaluating early Lyme disease. However, IgM antibodies may not be detectable during the first few days after a tick bite, and false-positive results may occur due to cross-reacting antibodies from other infections or autoimmune diseases.

The IgM ELISA is a screening test, not a confirmatory test. According to current recommendations, positive or equivocal IgM ELISA results should be confirmed with an Immunoblot (Western Blot or line immunoblot) or another approved second-tier assay. In patients with the classic erythema migrans rash, Lyme disease is primarily diagnosed clinically, and treatment should not be delayed while waiting for laboratory results.

Benefits of the Test

• Detects early IgM antibodies against Borrelia burgdorferi.
• Useful for screening suspected early Lyme disease.
• Requires only a simple blood sample.
• Supports early diagnosis after tick exposure.
• Highly sensitive screening method.
• Complements confirmatory Immunoblot testing.
• Assists clinicians in early evaluation.
• Supports timely treatment decisions.

Why Doctors Recommend This Test

Doctors recommend the Lyme Disease IgM ELISA Test for patients with recent tick exposure, early symptoms of Lyme disease, or as part of the recommended two-tier testing strategy.

Preparation Before the Test

No special preparation is required.

You may eat and drink normally unless instructed otherwise. Inform your healthcare provider about recent tick bites, travel to Lyme-endemic regions, previous Lyme disease, antibiotic treatment, and current symptoms. A blood sample is collected from a vein for laboratory analysis.

Normal Reporting Time

Typically: 2–5 Working Days

Reporting time may vary depending on laboratory methodology.

Who Should Take This Test?

This test may be recommended for:

• Individuals with recent tick bites.
• Patients with early symptoms of Lyme disease.
• People with fever after tick exposure.
• Individuals with erythema migrans and atypical presentation.
• Patients with unexplained fatigue following tick bites.
• Travelers returning from endemic regions.
• Individuals requiring Lyme disease screening.
• Patients referred by infectious disease specialists.
• Individuals with suspected early Lyme disease.
• Anyone advised by their healthcare provider.